Skip to content

TNX-355, new entry inhibitor, effective in highly treatment-experienced patients

Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

Merck launches expanded access programme for integrase inhibitor

Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year

Lipodystrophy study halted after patient death

Efavirenz / Truvada three-in-one pill licensed in US as Atripla

15th HIV Resistance Workshop: resistance to integrase inhibitors

15th HIV Resistance Workshop: new NRTIs